Pasteurised Akkermansia shows gut and mood benefits: Mouse study

By Stephen Daniells

- Last updated on GMT

© LightFieldStudios / Getty Images
© LightFieldStudios / Getty Images

Related tags Akkermansia muciniphila Probiotics Gut health

Supplementation with pasteurized Akkermansia may reduce gut permeability, anxiety-like behaviour and memory impairment in animal models of irritable bowel syndrome (IBS), says a new study.

IBS disturbs communication along the microbiota-gut-brain axis in IBS, with well-documented changes in the microbiota composition accompanied by effects such as anxiety and depression symptom.

A new study published in Gut Microbes​ indicated that eight to ten days of supplementation with the pasteurised strain of Akkermansia muciniphila​ significantly reduced these detrimental effects, and also reduced chronic abdominal pain in laboratory mice with IBS.

“Our study was based on the characterization of the neuromodulatory activity of pasteurized A. muciniphila​ bacteria in an attempt to find a new non-pharmacological approach to relieve chronic abdominal pain and anxio-depressive symptoms in IBS subjects,”  the researchers wrote.

Akkermansia

Akkermansia​, and the A. muciniphila​ species in particular, has attracted growing interest for its health-promoting effects. In rodents, treatment with A. muciniphila​ reduces obesity and related disorders, such as glucose intolerance, insulin resistance and gut permeability.

The species A. muciniphila​ reportedly has an abundance of about 3% in the human colon​, and its abundance in the intestinal mucus layer is inversely correlated with BMI, type 1 diabetes and bowel disease in humans. Akkermansia​ is known to produce nutrients that feed intestinal cells responsible for producing the intestinal mucus layer, helping to maintain healthy intestinal barrier function, control gut permeability, and control low grade inflammation in the gut.

Much of the research into the species has been conducted in Belgium at the Catholic University of Louvain, and a spin-off company called The Akkermansia Company​ was launched several years ago focusing on commercial development of A. muciniphila​ products.

The company achieved novel foods approval in Europe for pasteurised A. muciniphila​ in 2021​.

The new study was conducted by scientists from the University of Clermont Auvergne, Wageningen University, The Akkermansia Company, Université Catholique de Louvain using pasteurized A. muciniphila​ MucT​ (ATTC BAA-835). The Akkermansia Company co-funded the study.

Study details

The study employed two clinically relevant animal models to mimic IBS-like symptoms, both of which were used to assess gut permeability, colonic sensitivity, faecal microbiota composition and expression of IL-22 in the colon (IL-22 is a fundamental mediator in inflammation). Lab mice were fed the two different doses of the pasteurized probiotic for eight or ten consecutive days.  The neuromodulation ability of pasteurized A. muciniphila​ was also assessed.

Results showed that Akkermansia supplementation in both models of IBS was association with a significant reduction in colonic hypersensitivity, with the intestinal barrier function reinforced in both models.

The researchers also observed beneficial effects on anxiety-like behaviour and memory defects in lab mice.

“Our study is the first to describe the direct beneficial effect of pasteurized A. muciniphila​ on colonic sensitivity and to suggest that it could relieve chronic abdominal pain,” the researchers concluded.

Source: Gut Microbes
16​:1, doi: 10.1080/19490976.2023.2298026
“Pasteurized Akkermansia muciniphila​ improves irritable bowel syndrome-like symptoms and related behavioral disorders in mice”
Authors: M. Meynier, et al.

 

 

                                                                                                                                       

Related news

Related products

show more

New digestive wellness solution with clinical evidence

New digestive wellness solution with clinical evidence

Content provided by Symrise AG | 31-May-2024 | Product Brochure

16% of adults across the globe are suffering from constipation¹. Functional gastrointestinal disorders are a worldwide issue, impacting the life of 15,2%...

Related suppliers

Follow us

Products

View more

Webinars